Lecture Notes on Community-Acquired Pneumonia (CAP) and Hospital-Acquired Pneumonia (HAP)

Assignment Due: Submit by 11:59 PM. Failure to submit results in a score of zero; this assignment is worth 4% of the final grade and serves as practice for the upcoming test.
Exam Details: Exam 2 coverage includes material until tomorrow. Dr. Holger will cover COVID and influenza as part of respiratory infections. Exam 2 will take place next Wednesday.

Patient Profile: 53-year-old male presenting with productive cough, shortness of breath, and fevers.
Diagnosis: Clinical findings indicative of pneumonia; treated as CAP.

Classification Criteria: It is critical to determine if pneumonia is severe or non-severe, which dictates whether treatment occurs in an outpatient or inpatient setting.
Non-Severe Pneumonia Treatment:
- General Rule: Beta-lactam (e.g., Ampicillin or Unasyn) + Macrolide (e.g., Azithromycin)
- Doxycycline may also be combined with beta-lactams.
- For fluoroquinolone monotherapy—use recommended types like Levofloxacin or Moxifloxacin; however, NOT Zosyn (Piperacillin/Tazobactam) as it does not cover Strep pneumonia.

Recommended Inpatient Regimen for Non-Severe CAP:
- Beta-lactam + Macrolide:
- Example: Unasyn + Azithromycin
- Cephalosporins:
- Commonly used: Ceftriaxone—advantageous due to once-daily dosing and no renal adjustment requirement.
- Monitoring Cautions:
- Note the QTc prolongation associated with some antibiotics (fluoroquinolones, macrolides).

Identifying Severe CAP:
- Indicators include criteria for emergency intubation or intensive treatment.
- Recommended Regimen for Severe CAP: Beta-lactam + Atypical Coverage
- Typical Atypical Coverage Agents: Macrolides or fluoroquinolones.
- Monotherapy with fluoroquinolones is not recommended; combination with beta-lactam is essential.

Potential Risk Factors:
- Whether or not the patient has prior MRSA risk factors (e.g., previous respiratory cultures, hospitalization, etc.) may necessitate the addition of Vancomycin or Linezolid.
Understanding Clinical Application:
- Not all agents that cover MRSA are appropriate for pneumonia treatment.

Differentiation of Therapy Needs:
- Identify additional antibiotic coverage based on specific risk factors for MRSA and Pseudomonas.
- Depending on the response to treatment, de-escalation may happen after culturing shows a negative MRSA result; hence, therapy may shift accordingly.

Monitoring:
- Blood and respiratory cultures recommended for severely ill patients with drastic symptoms or failure to improve under treatment.
Duration of Therapy: Recommended a minimum of 5-7 days, depending on clinical stability and symptom relief.
Imaging Protocols: Routine follow-up chest X-rays are not advised unless clinically necessary to avoid unnecessary interventions.

Immunocompromised Patients: Susceptibility and organisms will change significantly; fungi and atypical organisms can be significant.

Azithromycin Dosing Regimen: 500 mg on the first day, followed by 250 mg daily for the next four days.
Amoxicillin: High doses recommended for non-comorbid patients; 1g three times per day; 500 mg recommended for some.
Doxycycline Considerations: Not associated with QTc prolongation, also advised against in pediatric patients (<8 years).

General Treatment Considerations:
- Follow guidelines that increase antibiotic efficacy against epidemiologically relevant microbiota.
- Always treat suspected HAP or BAP with broad-spectrum beta-lactams and evaluate the need for MRSA coverage.
Length of Hospital Stay and Costs: Be aware that increased LOS can reflect the institution's quality metrics; pneumonia can lead to serious financial repercussions.